Tumor size was significantly reduced (nearly half) in the LV‐sh‐ANXA9 group relative to the LV‐NC group in the xenograft model (p < 0.01), suggesting that ANXA9 silencing repressed tumor progression in BCA progression in vitro and in vivo. Here, ANXA9 is linked to neoplasm.